Journey Medical targets expanded Emrosi coverage and EBITDA growth through 2026 amid robust prescription demand (NASDAQ:DERM)March 26, 2026
Share Facebook Twitter LinkedIn Pinterest Email SemiLEDs press release (NASDAQ:LEDS): Q2 GAAP EPS of $0.05. Revenue of $10.87M (+762.7% Q/Q). The company’s cash and cash equivalents were $2.4 million at February 28, 2025, compared to $1.2 million at the end of the first quarter of fiscal 2025.
Journey Medical targets expanded Emrosi coverage and EBITDA growth through 2026 amid robust prescription demand (NASDAQ:DERM)March 26, 2026
Modiv Industrial outlines accelerated asset recycling, targets 100% manufacturing portfolio within 24 months (NYSE:MDV)March 26, 2026
